Health Affairs, 25, no. 5 (2006): 1340-1346 doi: 10.1377/hlthaff.25.5.1340 © 2006 by Project HOPE	New Online   Pay Cuts For Medicare Docs   Access To Care Woes   Public Coverage More Efficient   Empowering Consumers

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Monroe, C. D. Articles by Wagner, R. Search for Related Content PubMed PubMed Citation Articles by Monroe, C. D. Articles by Wagner, R. Related Collections Insurance Market Access To Care Business Of Health Chronic Care Consumer Issues Insurance Coverage Managed Care Managed Care - Consumers Pharmaceuticals Quality Of Care Research And Technology Health Spending

Specialty Drugs

PERSPECTIVE

Kaiser Permanente’s Evaluation And Management Of Biotech Drugs: Assessing, Measuring, And Affecting Use

Two decades into the age of high-cost biotechnology medications, health care organizations are challenged to provide safe, effective treatment while managing costs. In a market lacking generic biotech drugs, health care organizations have few opportunities to negotiate reduced pricing; other strategies must be devised to manage use. Kaiser Permanente leverages its integrated health care delivery system to deploy management tools for costly therapies: evidence analysis, usage measurements, and multidisciplinary planning. Evidence-based medicine and realization of value provided by new therapies will depend on data capture and outcomes measurement, tools that are crucial to Kaiser Permanente’s management of biotechnologies and effective use of members’ financial resources.

                      What's this?